Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus EOHILIA.
DEXASPORIN vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid